SP
CMMB

SmartHarvest Portfolios’s Chemomab Therapeutics CMMB Stock Holding History

SmartHarvest Portfolios’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,566
Closed -$22.9K – 466
2026
Q1 		$22.9K Buy
+14,566
New +$24.9K 0.01% 381

Other funds holding CMMB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $161M AUM
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

SmartHarvest Portfolios's CMMB Position: Q2 2026 in Review

SmartHarvest Portfolios sold out of Chemomab Therapeutics (CMMB) in Q2 2026, closing a stake of 14,566 shares — an estimated $22.9K sold.

SmartHarvest Portfolios first reported a position in CMMB in Q1 2026 and held it in 1 quarter. The position peaked at $22.9K in Q1 2026. 13 funds tracked by Wall St. Rank hold CMMB as of Q2 2026.

  • SmartHarvest Portfolios reported no remaining Chemomab Therapeutics position as of Q2 2026 after selling out during the quarter.
  • SmartHarvest Portfolios sold 14,566 Chemomab Therapeutics shares in Q2 2026, an estimated $22.9K.
  • SmartHarvest Portfolios first reported a position in Chemomab Therapeutics in Q1 2026 and held it in 1 quarter.
  • SmartHarvest Portfolios's Chemomab Therapeutics position peaked at $22.9K in Q1 2026.
  • 13 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2026.

Based on SmartHarvest Portfolios's 13F filing for Q2 2026, filed 4 Aug 2026.